Beyond Air (STU:48L0) Debt-to-Asset : 0.39 (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Beyond Air Debt-to-Asset?

Beyond Air's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.93 Mil. Beyond Air's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €9.88 Mil. Beyond Air's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was €27.81 Mil. Beyond Air's debt to asset for the quarter that ended in Mar. 2025 was 0.39.

Beyond Air Debt-to-Asset Historical Data

The historical data trend for Beyond Air's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Debt-to-Asset Chart

Beyond Air Annual Data

Trend

Jun16

Dec17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Asset

Get a 7-Day Free Trial

0.17

0.04

0.05

0.31

0.39

Beyond Air Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.31	0.38	0.25	0.06	0.39

Competitive Comparison of Beyond Air's Debt-to-Asset

For the Medical Devices subindustry, Beyond Air's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beyond Air's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Beyond Air's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Beyond Air Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Beyond Air's Debt-to-Asset for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.93	+	9.882)	/	27.807
	=	0.39

Beyond Air's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.93	+	9.882)	/	27.807
	=	0.39

Beyond Air (STU:48L0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Beyond Air Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Beyond Air's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Beyond Air Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (STU:48L0) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

XAIR:USA

Address

900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530

Website

https://www.beyondair.net

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Headlines

No Headlines